

**THROMBUS IN PERIPHERAL ARTERY DISEASE (PAD)  
PREVALENCE AND MARKET  
A SIGNIFICANT BUT RECENTLY NEGLECTED PROBLEM**

Mary L. Yost  
THE SAGE GROUP  
404-520-6652

THE SAGE GROUP, LLC  
23 Ridge Rd  
Beaufort SC 29907

Copyright Pending  
2019

All rights reserved, including the right of reproduction  
in whole or in part in any form.

## INDEX OF TABLES

Table 1: 2015-2030 Prevalence of Thrombus in Symptomatic Patients and Limbs	5.
Table 2: 2015-2030 Prevalence of Thrombus by Disease Severity in Patients and Limbs	5.
Table 3: 2015-2030 Thrombus Treatment Market in Patients and Limbs Assuming 20% Diagnosed and Treated	6.
Table 4: 2015-2030 Thrombus Treatment Market by Disease Severity in Patients and Limbs Assuming 20% Diagnosed and Treated	6.
Table 5: 2015-2030 Market for Intermittent Claudication and Critical Limb Ischemia Patients Requiring Antithrombotic Risk Factor Modification Therapies	7.
Table 6: 2015-2030 Market for Asymptomatic Peripheral Artery Disease Patients Requiring Antithrombotic Risk Factor Modification Therapies	8.
Table 7: AHA Conventional and Modified Atherosclerotic Plaque Classification System	11.
Table 8: Imaging Technologies to Measure Lesion Size and Characteristics	12.
Table 9: IVUS Virtual Histology Plaque Components, Stability and Depiction	13.
Table 10 : Criteria for Defining Vulnerable Plaque	16.
Table 11: Plaque Rupture in Lower Limb Arteries	18.
Table 12: Prevalence of Thrombus in Above Knee Arteries Based on Plaque Disruption/Rupture	22.
Table 13: Prevalence of Thrombus in Symptomatic Patients Based on Identification of Thrombus	22.
Table 14: Percent Prevalence of Thrombus in Critical Limb Ischemia Arteries with Luminal Stenosis $\geq 70\%$ by Location	23.
Table 15: 2015-2030 Prevalence of Thrombus in Intermittent Claudication and Critical Limb Ischemia Patients	24.
Table 16: 2015-2030 Prevalence of Thrombus in Limbs in Intermittent Claudication and Critical Limb Ischemia	25.
Table 17: 2015-2030 Patient Market for Thrombus Treatment in Symptomatic Peripheral Artery Disease	25.
Table 18: 2015-2030 Limb Market for Thrombus Treatment in Symptomatic Peripheral Artery Disease	26.
Table 19: 2015-2030 Prevalence of Intermittent Claudication and Critical Limb Ischemia Patients Requiring Antithrombotic Risk Factor Modification Therapies	27.

Table 20: 2015-2030 High Market Estimates for Symptomatic Patients Requiring Antithrombotic Risk Factor Modification Therapies 28.

Table 21: 2015-2030 Patient Market for Antithrombotic Therapy in Asymptomatic Peripheral Artery Disease 30.

## CONTACT INFORMATION

Mary L. Yost  
President  
Telephone (404) 520-6652  
[yost@thesagegroup.us](mailto:yost@thesagegroup.us)